Overview

A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b)

Status:
Not yet recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this healthy volunteers drug-drug interaction study is to assess the CYP1A2 and CYP3A4 perpetrator interaction potential and CYP1A2 victim potential of TEV-56286 (anle138b).

Phase:

Phase 1

Details

Lead Sponsor:

MODAG GmbH

Collaborators:

Aptuit (Verona) Srl, an Evotec Company
Quotient Sciences
Teva Pharmaceutical Industries, Ltd.

Treatments:

Caffeine
Fluvoxamine
Midazolam